Comprehensive Stock Comparison
Compare Prime Medicine, Inc. (PRME) vs Alnylam Pharmaceuticals, Inc. (ALNY) Stock
Analyze side-by-side fundamentals, valuation, growth, and profitability to decide which stock is the better buy.
Selected Stocks
Add up to 10 tickers. Use presets or search to get started.
Quick Verdict
| Category | Winner | Why |
|---|---|---|
| Growth | PRME | 6.5% revenue growth vs ALNY's 65.2% |
| Quality / Margins | ALNY | 8.4% net margin vs PRME's -33.0% |
| Stability / Safety | ALNY | Beta 0.88 vs PRME's 1.88 |
| Dividends | Tie | Neither pays a meaningful dividend |
| Momentum (1Y) | PRME | +83.3% vs ALNY's +34.9% |
| Efficiency (ROA) | ALNY | 6.3% ROA vs PRME's -51.3%, ROIC 19.1% vs -260.5% |
Who Each Stock Is For
Income & stability
Growth exposure
Long-term compounding (10Y)
Sleep-well-at-night portfolio
Defensive / Recession hedge
Business Model
What each company does and how it makes money
Prime Medicine is a biotechnology company developing next-generation gene editing therapies using its proprietary Prime Editing technology. It aims to generate revenue through research collaborations, licensing deals, and potential future drug sales — though currently in pre-revenue stage with no commercial products. Its key advantage is the Prime Editing platform, which offers more precise and versatile gene editing than earlier CRISPR technologies, potentially enabling treatments for a wider range of genetic diseases.
Alnylam Pharmaceuticals is a biopharmaceutical company that develops and commercializes RNA interference (RNAi) therapeutics for rare genetic diseases. It generates revenue primarily from sales of its approved RNAi drugs — ONPATTRO, GIVLAARI, OXLUMO, and others — targeting conditions like hereditary transthyretin amyloidosis, acute hepatic porphyria, and primary hyperoxaluria. The company's key advantage is its pioneering RNAi technology platform and intellectual property estate, which creates a significant barrier to entry in the RNAi therapeutics space.
Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Financial Metrics Comparison
Side-by-side fundamentals across 2 stocks. BestLagging
Financial Scorecard
ALNY leads in 4 of 6 categories (Financial Metrics, Profitability & Efficiency). PRME leads in 1 (Valuation Metrics).
Financial Metrics (TTM)
ALNY is the larger business by revenue, generating $3.7B annually — 621.4x PRME's $6M. ALNY is the more profitable business, keeping 8.4% of every revenue dollar as net income compared to PRME's -33.0%. On growth, PRME holds the edge at +4.9% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | PRMEPrime Medicine, I… | ALNYAlnylam Pharmaceu… |
|---|---|---|
| RevenueTrailing 12 months | $6M | $3.7B |
| EBITDAEarnings before interest/tax | -$197M | $557M |
| Net IncomeAfter-tax profit | -$197M | $314M |
| Free Cash FlowCash after capex | -$115M | $465M |
| Gross MarginGross profit ÷ Revenue | -6.7% | +81.8% |
| Operating MarginEBIT ÷ Revenue | -34.1% | +13.5% |
| Net MarginNet income ÷ Revenue | -33.0% | +8.4% |
| FCF MarginFCF ÷ Revenue | -19.3% | +12.5% |
| Rev. Growth (YoY)Latest quarter vs prior year | +4.9% | +84.9% |
| EPS Growth (YoY)Latest quarter vs prior year | +27.0% | +3.1% |
Valuation Metrics
| Metric | PRMEPrime Medicine, I… | ALNYAlnylam Pharmaceu… |
|---|---|---|
| Market CapShares × price | $833M | $44.1B |
| Enterprise ValueMkt cap + debt − cash | $691M | $45.4B |
| Trailing P/EPrice ÷ TTM EPS | -2.80x | 142.88x |
| Forward P/EPrice ÷ next-FY EPS est. | — | 48.96x |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | 81.44x |
| Price / SalesMarket cap ÷ Revenue | 279.26x | 11.87x |
| Price / BookPrice ÷ Book value/share | 3.58x | 56.82x |
| Price / FCFMarket cap ÷ FCF | — | 94.70x |
Profitability & Efficiency
ALNY delivers a 39.8% return on equity — every $100 of shareholder capital generates $40 in annual profit, vs $-122 for PRME. PRME carries lower financial leverage with a 0.27x debt-to-equity ratio, signaling a more conservative balance sheet compared to ALNY's 3.76x. On the Piotroski fundamental quality scale (0–9), ALNY scores 6/9 vs PRME's 4/9, reflecting solid financial health.
| Metric | PRMEPrime Medicine, I… | ALNYAlnylam Pharmaceu… |
|---|---|---|
| ROE (TTM)Return on equity | -121.9% | +39.8% |
| ROA (TTM)Return on assets | -51.3% | +6.3% |
| ROICReturn on invested capital | -2.6% | +19.1% |
| ROCEReturn on capital employed | -102.0% | +15.3% |
| Piotroski ScoreFundamental quality 0–9 | 4 | 6 |
| Debt / EquityFinancial leverage | 0.27x | 3.76x |
| Net DebtTotal debt minus cash | -$142M | $1.3B |
| Cash & Equiv.Liquid assets | $182M | $1.7B |
| Total DebtShort + long-term debt | $41M | $3.0B |
| Interest CoverageEBIT ÷ Interest expense | — | 7.20x |
Total Returns (with DRIP)
A $10,000 investment in ALNY five years ago would be worth $22,381 today (with dividends reinvested), compared to $3,006 for PRME. Over the past 12 months, PRME leads with a +83.3% total return vs ALNY's +34.9%. The 3-year compound annual growth rate (CAGR) favors ALNY at 20.3% vs PRME's -34.5% — a key indicator of consistent wealth creation.
| Metric | PRMEPrime Medicine, I… | ALNYAlnylam Pharmaceu… |
|---|---|---|
| YTD ReturnYear-to-date | +30.9% | -16.8% |
| 1-Year ReturnPast 12 months | +83.3% | +34.9% |
| 3-Year ReturnCumulative with dividends | -71.9% | +73.9% |
| 5-Year ReturnCumulative with dividends | -69.9% | +123.8% |
| 10-Year ReturnCumulative with dividends | -45.6% | +468.4% |
| CAGR (3Y)Annualised 3-year return | -34.5% | +20.3% |
Risk & Volatility
ALNY is the less volatile stock with a 0.88 beta — it tends to amplify market swings less than PRME's 1.88 beta. A beta below 1.0 means the stock typically moves less than the S&P 500.
| Metric | PRMEPrime Medicine, I… | ALNYAlnylam Pharmaceu… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.88x | 0.88x |
| 52-Week HighHighest price in past year | $6.94 | $495.55 |
| 52-Week LowLowest price in past year | $1.11 | $205.87 |
| % of 52W HighCurrent price vs 52-week peak | +66.6% | +67.2% |
| RSI (14)Momentum oscillator 0–100 | 65.6 | 43.8 |
| Avg Volume (50D)Average daily shares traded | 2.5M | 1.2M |
Analyst Outlook
Wall Street rates PRME as "Buy" and ALNY as "Buy". Consensus price targets imply 273.4% upside for PRME (target: $17) vs 38.5% for ALNY (target: $461).
| Metric | PRMEPrime Medicine, I… | ALNYAlnylam Pharmaceu… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy |
| Price TargetConsensus 12-month target | $17.25 | $461.06 |
| # AnalystsCovering analysts | 9 | 51 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Historical Charts
Charts are rendered on first load. Hover for details.
Chart 1Total Return — 5 Years (Rebased to 100)
| Stock | Oct 22 | Feb 26 | Change |
|---|---|---|---|
| Prime Medicine, Inc. (PRME) | 100 | 24.72 | -75.3% |
| Alnylam Pharmaceuti… (ALNY) | 100 | 159.12 | +59.1% |
Alnylam Pharmaceuti… (ALNY) returned +124% over 5 years vs Prime Medicine, Inc. (PRME)'s -70%. A $10,000 investment in ALNY 5 years ago would be worth $22,381 today (including dividends reinvested).
Chart 2Revenue Growth — 10 Years
| Stock | 2016 | 2025 | Change |
|---|---|---|---|
| Prime Medicine, Inc. (PRME) | $0.00 | $3M | — |
| Alnylam Pharmaceuti… (ALNY) | $47M | $3.7B | +7775.4% |
Alnylam Pharmaceuticals, Inc.'s revenue grew from $47M (2016) to $3.7B (2025) — a 62.4% CAGR.
Chart 3Net Margin Trend — 10 Years
| Stock | 2016 | 2025 | Change |
|---|---|---|---|
| Prime Medicine, Inc. (PRME) | -65.5% | -65.7% | -0.3% |
| Alnylam Pharmaceuti… (ALNY) | -8.7% | 8.4% | +197.1% |
Alnylam Pharmaceuticals, Inc.'s net margin went from -9% (2016) to 8% (2025).
Chart 4EPS Growth — 10 Years
| Stock | 2016 | 2025 | Change |
|---|---|---|---|
| Prime Medicine, Inc. (PRME) | -0.03 | -1.65 | -5556.2% |
| Alnylam Pharmaceuti… (ALNY) | -4.79 | 2.33 | +148.6% |
Alnylam Pharmaceuticals, Inc.'s EPS grew from $-4.79 (2016) to $2.33 (2025).
Chart 5Free Cash Flow — 5 Years
Prime Medicine, Inc. generated $-130M FCF in 2024 (-240% vs 2021). Alnylam Pharmaceuticals, Inc. generated $465M FCF in 2025 (+165% vs 2021).
PRME vs ALNY: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is PRME or ALNY a better buy right now?
Alnylam Pharmaceuticals, Inc. (ALNY) offers the better valuation at 142.9x trailing P/E (49.0x forward), making it the more compelling value choice. Analysts rate Prime Medicine, Inc. (PRME) a "Buy" — based on 9 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — PRME or ALNY?
Over the past 5 years, Alnylam Pharmaceuticals, Inc. (ALNY) delivered a total return of +123.8%, compared to -69.9% for Prime Medicine, Inc. (PRME). A $10,000 investment in ALNY five years ago would be worth approximately $22K today (assuming dividends reinvested). Over 10 years, the gap is even starker: ALNY returned +468.4% versus PRME's -45.6%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — PRME or ALNY?
By beta (market sensitivity over 5 years), Alnylam Pharmaceuticals, Inc. (ALNY) is the lower-risk stock at 0.88β versus Prime Medicine, Inc.'s 1.88β — meaning PRME is approximately 114% more volatile than ALNY relative to the S&P 500. On balance sheet safety, Prime Medicine, Inc. (PRME) carries a lower debt/equity ratio of 27% versus 4% for Alnylam Pharmaceuticals, Inc. — giving it more financial flexibility in a downturn.
04Which has better profit margins — PRME or ALNY?
Alnylam Pharmaceuticals, Inc. (ALNY) is the more profitable company, earning 8.4% net margin versus -65.7% for Prime Medicine, Inc. — meaning it keeps 8.4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ALNY leads at 13.5% versus -67.9% for PRME. At the gross margin level — before operating expenses — PRME leads at 100.0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
05Is PRME or ALNY more undervalued right now?
Analyst consensus price targets imply the most upside for PRME: 273.4% to $17.25.
06Which pays a better dividend — PRME or ALNY?
None of the stocks in this comparison currently pay a material dividend. All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is PRME or ALNY better for a retirement portfolio?
For long-horizon retirement investors, Alnylam Pharmaceuticals, Inc. (ALNY) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.88), +468.4% 10Y return). Prime Medicine, Inc. (PRME) carries a higher beta of 1.88 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (ALNY: +468.4%, PRME: -45.6%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between PRME and ALNY?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that beat both.